CD22 and Immunodeficiency: Several studies reported the development of strong anti-spike T cell responses upon vaccination in patients with severe humoral immune deficiencies, including patients treated with anti-CD20 antibody and CAR-T cell therapies targeting CD19 and CD22 (44, 45).